Generics

Imatinib mesylate tablets have a market value of roughly $324 million for the 12 months ended January 2021, according to IQVIA.

Prilosec delayed-release capsules and its generics had a market value of $104.5 million for the 12-month period ended January 2021, according to IQVIA.

Thorazine had a market value of roughly $108.6 million for the 12 months ended January 2021, according to IQVIA.

The product is being recalled due to a market complaint received, stating that one bottle labeled as 30-count telmisartan tablets 20 mg incorrectly contained 30 tablets of 40-mg telmisartan tablets.

A study from Avalere, funded by the Association for Accessible Medicines, found that in 2021, Medicare Part D plans placed generic prescription drugs on generic tiers 45% of the time, a decrease from 64% in 2016.

Organon, a proposed spinoff of Merck's women's health, biosimilars and established brands businesses, intends to appoint a majority-female board of directors.

Biogen and Alkermes claim that Teva’s generic infringes three patents that protect Vumerity, which Alkermes licenses exclusively to Biogen.

Cardizem had a market value of approximately $56.7 million for the 12 months ended January 2021, according to IQVIA.